ReviewPathology oncology research : POR1998
Diagnostics of multidrug resistance in cancer.
Review in Pathology oncology research : POR, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Characterisation of 3D Bioprinted Human Breast Cancer Model for In Vitro Drug and Metabolic Targeting.International journal of molecular sciences · 2022Article
- Multidrug Resistance in Mammals and Fungi-From MDR to PDR: A Rocky Road from Atomic Structures to Transport Mechanisms.International journal of molecular sciences · 2021Review
- Brown Seaweed Fucoidan in Cancer: Implications in Metastasis and Drug Resistance.Marine drugs · 2020Review
- A Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer.OncoTargets and therapy · 2020Review
- Induction/reversal of drug resistance in gastric cancer by non-coding RNAs (Review).International journal of oncology · 2019Review
- MicroRNAs: promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential.World journal of gastroenterology · 2014Review
- Assessment of Plasmodium falciparum PfMDR1 transport rates using Fluo-4.Journal of cellular and molecular medicine · 2014Article
- Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib.Cell death & disease · 2014Article
- Drug-induced trafficking of p-glycoprotein in human brain capillary endothelial cells as demonstrated by exposure to mitomycin C.PloS one · 2014Article
- Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers.Pharmaceutical research · 2010Article
- Paclitaxel nanocrystals for overcoming multidrug resistance in cancer.Molecular pharmaceutics · 2010Article
- Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.Small (Weinheim an der Bergstrasse, Germany) · 2009Article
- The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins.Pharmaceutical research · 2009Article
- Chemosensitization effects of simultaneous suppression of MDR1 and XIAP in multidrug resistant glioma cells.Medical oncology (Northwood, London, England) · 2008Article
- Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum.The EMBO journal · 2006Article
- Multidrug resistance transporters in the olfactory receptor neurons of Xenopus laevis tadpoles.The Journal of physiology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug resistance (MDR), caused by the overexpression of two membrane proteins, MDR1-Pgp and/or MRP, is a major obstacle in the chemotherapy of cancer. The proper laboratory diagnosis of clinical multidrug resistance is still an unresolved question, and this uncertainty, in a vicious cycle, does not allow the correct evaluation of the clinical relevance of the MDR phenomenon. More-over, inefficient MDR diagnostics hinders the development of effective resistance-modulation strategies. In this review, after describing the basic features of the MDR drug pump proteins, the currently employed diagnostic methods are discussed. We suggest that a quantitative, functional method developed in our laboratory may provide a major help in the laboratory assessment of cancer MDR.
Indexed as
Identifiers
9887354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.